Adrienne Waks, MD

Articles by Adrienne Waks, MD

HER2+ Metastatic Breast Cancer: Unmet Needs and Future Directions in Care

BySara M. Tolaney, MD, MPH,Nancy U. Lin, MD,Sarah Sammons, MD,Adrienne Waks, MD,Ayal A. Aizer, MD, MHS

January 27th 2023

Closing out their review of the HER2+ metastatic breast cancer treatment landscape, expert oncologists look forward to future evolutions in the paradigm.

Managing HER2+ Breast Cancer With Leptomeningeal Metastases

BySara M. Tolaney, MD, MPH,Nancy U. Lin, MD,Sarah Sammons, MD,Adrienne Waks, MD,Ayal A. Aizer, MD, MHS

January 27th 2023

Panelists center their discussion on the challenges inherent in managing leptomeningeal metastases in patients with HER2+ breast cancer.

Agents in Development for HER2+ Breast Cancer

BySara M. Tolaney, MD, MPH,Nancy U. Lin, MD,Sarah Sammons, MD,Adrienne Waks, MD,Ayal A. Aizer, MD, MHS

January 20th 2023

Experts share brief insights on novel agents in development for HER2+ breast cancer and consider how they may impact the treatment landscape.

Optimizing Care of Patients on T-DXd for HER2+ mBC With CNS Disease

BySara M. Tolaney, MD, MPH,Nancy U. Lin, MD,Sarah Sammons, MD,Adrienne Waks, MD,Ayal A. Aizer, MD, MHS

January 20th 2023

Centering discussion on trastuzumab deruxtecan use in HER2+ metastatic breast cancer, experts elucidate adverse event management and concurrent radiation therapy.

HER2+ Metastatic Breast Cancer: Guidance on MRI Use After CNS Radiation

BySara M. Tolaney, MD, MPH,Nancy U. Lin, MD,Sarah Sammons, MD,Adrienne Waks, MD,Ayal A. Aizer, MD, MHS

January 13th 2023

A brief review on how best to use MRI following CNS-directed radiation therapy in patients with HER2+ metastatic breast cancer.

Patient Case 3: HER2+ Metastatic Breast Cancer With CNS Disease

BySara M. Tolaney, MD, MPH,Nancy U. Lin, MD,Sarah Sammons, MD,Adrienne Waks, MD,Ayal A. Aizer, MD, MHS

January 13th 2023

Following review of the final patient scenario, panelists consider later-line treatment options in the setting of multiply relapsed HER2+ metastatic breast cancer.

Novel Combination Strategies in HER2+ Metastatic Breast Cancer With CNS Disease

BySara M. Tolaney, MD, MPH,Nancy U. Lin, MD,Sarah Sammons, MD,Adrienne Waks, MD,Ayal A. Aizer, MD, MHS

January 6th 2023

Comprehensive review of novel combination treatment strategies being explored for patients with HER2+ breast cancer and brain metastases.

HER2+ mBC With CNS Disease: Sequencing Therapy After Progression on Tucatinib

BySara M. Tolaney, MD, MPH,Nancy U. Lin, MD,Sarah Sammons, MD,Adrienne Waks, MD,Ayal A. Aizer, MD, MHS

January 6th 2023

Panelists reflect on sequencing therapy for HER2+ metastatic breast cancer following disease progression on the tucatinib, trastuzumab and capecitabine regimen.

HER2CLIMB: Role of Tucatinib in Treating HER2+ mBC With CNS Disease

BySara M. Tolaney, MD, MPH,Nancy U. Lin, MD,Sarah Sammons, MD,Adrienne Waks, MD,Ayal A. Aizer, MD, MHS

December 30th 2022

A panel of expert oncologists highlight the use of the tucatinib, trastuzumab and capecitabine regimen that was investigated in the HER2CLIMB trial to manage patients with HER2+ breast cancer and brain metastases.

HER2+ Metastatic Breast Cancer: Role of Radiation Therapy in Managing CNS Disease

BySara M. Tolaney, MD, MPH,Nancy U. Lin, MD,Sarah Sammons, MD,Adrienne Waks, MD,Ayal A. Aizer, MD, MHS

December 30th 2022

Expert perspectives on the respective role of radiation therapy to manage brain metastases in the setting of HER2+ breast cancer.

Factors in Selecting Therapy for HER2+ Metastatic Breast Cancer With CNS Disease

BySarah M. Tolaney, MD, MPH,Nancy U. Lin, MD,Sarah Sammons, MD,Adrienne Waks, MD,Ayal A. Aizer, MD, MHS

December 23rd 2022

Shared consideration on the factors that dictate selection of optimal therapy for patients with HER2+ breast cancer and brain metastases.

Patient Case 2: HER2+ Breast Cancer With CNS Metastases

BySarah M. Tolaney, MD, MPH,Nancy U. Lin, MD,Sarah Sammons, MD,Adrienne Waks, MD,Ayal A. Aizer, MD, MHS

December 23rd 2022

Switching to a patient case of brain metastases in HER2+ breast cancer, panelists highlight available therapeutic strategies in this setting.

Strategies to Identify and Delay Brain Metastases in HER2+ Breast Cancer

BySarah M. Tolaney, MD, MPH,Nancy U. Lin, MD,Sarah Sammons, MD,Adrienne Waks, MD,Ayal A. Aizer, MD, MHS

December 16th 2022

A brief review on how best to identify, delay, or avoid brain metastases in patients diagnosed with metastatic HER2+ breast cancer.

HER2+ Metastatic Breast Cancer: Factors in Selecting Optimal Therapy

BySarah M. Tolaney, MD, MPH,Nancy U. Lin, MD,Sarah Sammons, MD,Adrienne Waks, MD,Ayal A. Aizer, MD, MHS

December 16th 2022

Having outlined available treatment options for patients with HER2+ metastatic breast cancer, expert panelists share which factors help to select optimal therapy.